These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38971910)

  • 1. Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies.
    Jakubek P; Pakula B; Rossmeisl M; Pinton P; Rimessi A; Wieckowski MR
    Intern Emerg Med; 2024 Aug; 19(5):1473-1491. PubMed ID: 38971910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes.
    Stienstra R; Haim Y; Riahi Y; Netea M; Rudich A; Leibowitz G
    Diabetologia; 2014 Aug; 57(8):1505-16. PubMed ID: 24795087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
    Stefan N; Hartleb M; Popovic B; Varona R
    Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
    Sourianarayanane A; Brydges CR; McCullough AJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102402. PubMed ID: 38909684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target acquired: Selective autophagy in cardiometabolic disease.
    Evans TD; Sergin I; Zhang X; Razani B
    Sci Signal; 2017 Feb; 10(468):. PubMed ID: 28246200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Zhao S; Guo Y; Yin X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review.
    Kaur M; Murugesan S; Singh S; Uy KN; Kaur J; Mann N; Sekhon RK
    Cureus; 2023 Dec; 15(12):e50118. PubMed ID: 38192918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy in metabolic disease and ageing.
    Kitada M; Koya D
    Nat Rev Endocrinol; 2021 Nov; 17(11):647-661. PubMed ID: 34508250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch M; Roden M; Kahl S
    Metabolism; 2024 Aug; 157():155937. PubMed ID: 38782182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.
    Ramos-Molina B; Rossell J; Pérez-Montes de Oca A; Pardina E; Genua I; Rojo-López MI; Julián MT; Alonso N; Julve J; Mauricio D
    Front Endocrinol (Lausanne); 2024; 15():1400961. PubMed ID: 38962680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway.
    Liu H; Javaheri A; Godar RJ; Murphy J; Ma X; Rohatgi N; Mahadevan J; Hyrc K; Saftig P; Marshall C; McDaniel ML; Remedi MS; Razani B; Urano F; Diwan A
    Autophagy; 2017; 13(11):1952-1968. PubMed ID: 28853981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy and Mitochondria in Obesity and Type 2 Diabetes.
    Sarparanta J; García-Macia M; Singh R
    Curr Diabetes Rev; 2017; 13(4):352-369. PubMed ID: 26900135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction-associated steatotic liver disease.
    Bergheim I; Moreno-Navarrete JM
    Eur J Clin Invest; 2024 Jul; 54(7):e14224. PubMed ID: 38634717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.